Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Dana-Farber Cancer Institute Stories

2013-06-25 12:00:28

A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes (MDS) – the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia. Using mathematical models to analyze hundreds of MDS cases from around the world, the researchers found reduced intensity transplants...

2013-06-18 10:30:01

Researchers believe the 'undruggable' may be druggable Harvard Stem Cell Institute (HSCI) researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity. The gene, SALL4, gives stem cells their ability to continue dividing as stem cells rather than becoming mature cells. Typically, cells only express SALL4 during embryonic development, but the gene is...

2013-06-18 10:28:32

Study suggests low-risk patients can forgo immediate treatment Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital. Writing in the June 18 issue of the Annals of Internal Medicine, the authors said their statistical...

2013-06-06 16:27:21

Partnership Seeks to Accelerate Development of Innovative Therapies WHITE PLAINS, N.Y., June 6, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This groundbreaking Blood Cancer Research Partnership (BCRP) will bring clinical trials closer to where patients live...

2013-05-03 23:18:19

Voices Against Brain Cancer, an organization dedicated to brain tumor research and advocacy, comments on an article discussing a new finding that may help in diagnosing and treating certain pediatric brain tumor cases. New York, NY (PRWEB) May 03, 2013 On May 3, Voices Against Brain Cancer (VABC), an organization dedicated to brain tumor research and advocacy, comments on an article discussing a new finding that may help doctors in classifying and treating certain pediatric brain tumors....

2013-05-01 15:32:07

A type of low-grade but sometimes lethal brain tumor in children has been found in many cases to contain an unusual mutation that may help to classify, diagnose and guide the treatment of the tumors, report scientists at Dana-Farber Cancer Institute. The researchers led a study of pediatric low-grade gliomas, samples of which were collected through an international consortium organized by brain tumor specialists at Dana-Farber/Children's Hospital Cancer Center. Their findings are being...

2013-04-25 16:30:57

Saul N. Weingart, MD, PhD to spearhead continuous quality improvement BOSTON, April 25, 2013 /PRNewswire-USNewswire/ -- Tufts Medical Center has appointed Saul N. Weingart, MD, PhD of Newton, Mass. as its next Chief Medical Officer. Weingart is a nationally renowned leader in the movement to improve hospital quality, currently serving as Vice President for Quality Improvement and Patient Safety at Dana-Farber Cancer Institute in Boston. He recently received one of the highest...

2013-04-24 15:40:46

Nearly two-thirds of children receiving stem cell transplants returned to the hospital within six months for treatment of unexplained fevers, infections or other problems, according to a study performed at Dana-Farber/Children's Hospital Cancer Center in Boston. Children who received donor cells were twice as likely to be readmitted as children who received their own stem cells. "No one had ever looked at these data in children," said Leslie E. Lehmann, MD, clinical director of pediatric...

2013-04-10 14:32:38

An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists will report at the annual meeting of the American Association for Cancer Research in Washington, April 6-10. The findings (abstract 4622) will be discussed in a minisymposium on Tuesday, April 9, 3:50 - 4:05...

2013-04-08 12:36:41

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10. The findings (Abstract LB-295) will be released at a press conference on Saturday, April 6, 3:00 p.m. ET, and later at an oral presentation on Tuesday, April 9, 3:35 —...